Patrick Lucy

As President and CEO of Lykan Bioscience, Patrick Lucy is responsible for driving dynamic growth of the company, developing infrastructure and efficiencies, and ensuring successful execution and delivery to our partners. Prior to joining Lykan, Patrick spent 19 years at Pfenex Inc., which began as a spin out from The Dow Chemical Company.  As a founder, Patrick was instrumental in the development of Pfenex’s strategy and evolution of the company’s portfolio which ultimately led to its acquisition by Ligand Pharmaceuticals. Previously, Patrick held roles in business development, operations, QC, validation and capital project management at Repligen Corporation, Celltech Biologics, Lonza Biologics and Collaborative BioAlliance.